The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
July 26, 2021
Berotralstat (Orladeyo) for Prevention of Hereditary Angioedema (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Berotralstat (Orladeyo) for Prevention of Hereditary Angioedema (online only)
July 26, 2021 (Issue: 1629)
Berotralstat (Orladeyo – Biocryst), an oral plasma
kallikrein inhibitor, has been approved by the FDA
for prevention of hereditary angioedema (HAE)
attacks in adults and children ≥12 years old. The
subcutaneously-injected plasma kallikrein...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.